NL-OMON42654
Completed
Phase 2
Safety, tolerability and sedative properties of single dose intranasal dexmedetomidine premedication in elderly subjects. - KUKIDEX-1
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- cardiovascular instability
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 48
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Planned for a maxillofacial procedure under general anesthetic in the UMCG planned on one of the planned study days
- •2\. Completed and cleared through the pre\-anesthetic screening as per the standard protocol
- •3\. Adult, men and women, over 65 years of age, inclusive.
- •4\. Body Mass Index (BMI) \* 17\.5 and \* 30\.5 kg/m2, inclusive, and a total body weight \>50 kg, at screening and check\-in.
- •5\. American Society of Anesthesiologists (ASA) Physical Status 1 or 2 as determined in the preprocedural anaesthesiological screening
- •6\. Obtain a score of I or II using the Modified Mallampati Scoring.
- •7\. Understand the study procedures in the informed consent form(s) (ICF(s)), and be willing and able to comply with the protocol.
- •8\. For inclusion in the beta blocked arm subjects only: taking beta blocking medication at home in any dose or prescription.
Exclusion Criteria
- •1\. For inclusion into the non\-beta blocked arm: taking any type of beta\-receptor blocking medication
- •2\. Contraindications for the use of dexmedetomidine
- •3\. Known intolerance to dexmedetomidine
- •4\. History or presence of significant cardiovascular disease (ASA \>2\), or significant cardiovascular disease risk factors, significant coronary artery disease, or any known genetic pre disposition to cardiac arrhythmia (including long QT syndrome.)
- •5\. History or presence of significant (ASA \>2\) pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological (inclusive of any seizure disorder), or psychiatric disease.
- •6\. History of any illness or medication use that, in the opinion of the PI, might confound the results of the study or pose an additional risk to the patient by their participation in the study.
- •7\. Surgery within the past 90 days prior to dosing judged by the PI to be clinically relevant.
- •8\. History of febrile illness within 5 days prior to dosing.
- •9\. History or presence of alcoholism or drug abuse within the past 2 years.
- •10\. Hypersensitivity or idiosyncratic reaction to components of dexmedetomidine, placebo components, or to compounds related to the study medications.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Is dexmedetomidine a safe medicine to calm elderly patients when they are waiting for an operation?Anxiety, preoperativeTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]EUCTR2015-004587-11-NLniversity Medical Center Groningen
Not yet recruiting
Not Applicable
Safety, tolerability and sedative properties of intranasal dexmedetomidine premedication in elderly peoplepharmacodynamicspharmacokineticshemodynamic changesNL-OMON27385niversity Medical Center Groningen48
Not yet recruiting
Not Applicable
Evaluation of Effectiveness and Side Effects of Single and Double surface Intensive Phototherapynon-hemolytic hyperbilirubinemia.Neonatal jaundice, unspecifiedP59.9IRCT20191203045595N1Hamedan University of Medical Sciences150
Recruiting
Not Applicable
Wetenschappelijk onderzoek naar de veiligheid van HPV-DNA vaccinatie en reactie van hetafweersysteem op deze vaccinatie bij patiënten met een HPV16-positieve afwijking aan deschaamlippen.NL-OMON29038KI-AV
Completed
Not Applicable
Safety, immunogenicity and clinical response of sig-HELP-E6SH/E7SH-kdel, injected in the epidermis by DNA tattoo, in HPV16-positive vulvar intraepithelial neoplasia: a phase I/II studyuVINvulvar dysplasia10038595NL-OMON47893Antoni van Leeuwenhoek Ziekenhuis14